Lamictal (Lamotrigine)

Lamotrigine works by inhibiting voltage‑gated sodium channels on neuronal membranes. This action limits the rapid influx of sodium ions during an action potential, stabilising the membrane and decreasing the release of excitatory neurotransmitters such as glutamate, which underlies its antiepileptic and mood‑stabilising effects.

The dosage of Lamictal is individualized and must be determined by a qualified prescriber. Dosing depends on the specific indication, patient age, renal function, and any concomitant medications that may affect lamotrigine levels. Patients should follow the prescribing clinician’s instructions and not adjust the dose on their own.

Lamotrigine is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate controlled studies in pregnant women. It may be used if the potential benefit justifies the potential risk. Limited data suggest it is excreted in breast milk; breastfeeding decisions should be made with a healthcare professional.

To place an order, submit an enquiry on the Lamictal product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Both lamotrigine and carbamazepine are sodium channel blockers used for epilepsy, but they differ in safety and tolerability. Lamotrigine has a lower risk of drug‑induced hyponatremia and fewer cognitive side effects, while carbamazepine can induce hepatic enzymes, affecting the metabolism of other drugs. Choice depends on individual patient factors and physician judgment.

Lamictal tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date. No special refrigeration is required for this oral formulation.

Lamictal is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water. Dosing schedules may involve gradual titration to minimise the risk of skin reactions, and the exact regimen is set by the healthcare provider.

The most serious adverse reactions include severe skin conditions such as Stevens‑Johnson syndrome and toxic epidermal necrolysis, which can be life‑threatening. Other rare but serious risks are blood dyscrasias, hepatic failure, and aseptic meningitis. Patients should seek immediate medical attention if they develop a widespread rash, fever, or unexplained symptoms.

Lamictal should be avoided in individuals with a known hypersensitivity to lamotrigine or any component of the formulation. Patients with a history of severe cutaneous adverse reactions to other antiepileptic drugs should use it with caution, and it is contraindicated in those taking contraindicated enzyme‑inducing agents without proper dose adjustment.